Canadian Cancer Trials Group Bulletins


Recent Publications

Canadian Cancer Trials Group OV.14 (NSGO OC9804) -- An International Randomized Phase III Trial of Paclitaxel/Epirubicin/Carboplatin Combination (TEC) versus Paclitaxel/Carboplatin (TC) in the Initial Treatment of Women with Advanced Ovarian Cancer

Lindemann K, Christensen RD, Vergote I, Stuart G, Izquierdo MA, Kaern J, Havsteen H, Eisenhauer E, Ridderheim M, Lopez AB, Hirte H, avall-Lundquvist E, Vrdoljak E, Green J, Kristensen GB. First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC) -- a gynecologic cancer intergroup study of the NSGO, EORTC GCG and Canadian Cancer Trials Group (ONLINE). Ann Oncol 2012.


Jin H, Zhao N, Tu D. Nonparametric confidence intervals for the ratio of marginal hazard rates of paired survival times. Biom J 54: 197-213, 2012.